Clinical Trial Update: Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating S-1 plus DC-CIK for unresectable locally advanced pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• DC-CIK
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Capital Medical University | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED